Dianthus Therapeutics ( (DNTH) ) just unveiled an announcement.
Dianthus Therapeutics has welcomed Steven Romano, M.D., to its Board as a Class III director and Science and Technology Committee member, with immediate effect. He’ll be incentivized with an option for 22,000 shares of common stock, vesting over three years, alongside a yearly cash compensation of $40,000 for board duties and an additional $5,000 for committee work. Dr. Romano is also set to receive regular equity awards and will be covered under a standard indemnification agreement.
See more insights into DNTH stock on TipRanks’ Stock Analysis page.
